首页 | 本学科首页   官方微博 | 高级检索  
检索        

枸杞糖肽治疗非酒精性脂肪肝的临床研究
引用本文:邢铭友,刘璐,钱冬斌,方建国,齐俊英,宋佩辉,田德英.枸杞糖肽治疗非酒精性脂肪肝的临床研究[J].中西医结合肝病杂志,2008,18(2):83-85.
作者姓名:邢铭友  刘璐  钱冬斌  方建国  齐俊英  宋佩辉  田德英
作者单位:1. 华中科技大学同济医学院附属同济医院感染科,湖北,武汉,430030
2. 华中科技大学同济医学院附属同济医院药学部,湖北,武汉,430030
摘    要:目的:探讨枸杞糖肽胶囊治疗非酒精性脂肪肝的疗效和药物不良反应。方法:采用随机对照研究,非酒精性脂肪肝患者82例,分为两组,每组41例,治疗组应用枸杞糖肽胶囊30mg po bid,对照组给予肝泰乐片200mg po tid,疗程均为6个月。治疗前和治疗3个月、6个月后记录两组患者的临床症状、肝功能(ALT、AST、TBil、GGT)、血脂(TG、TC、LDL-C、HDL-C)、B超结果,同时观察药物不良反应。结果:治疗组有效率70.7%,优于对照组(P〈0,05)。与3个月疗程比较差异有显著性意义(P〈0.05)。两组患者治疗后的ALT、AST、GGT明显下降,血脂各项指标明显改善,尤其在治疗组治疗前后比较差异有显著性意义(P〈0.01或P〈0.05)。用药过程中治疗组出现1例不良反应。结论:枸杞糖肽胶囊治疗非酒精性脂肪肝疗效显著,并且具有良好的安全性,延长疗程可增加疗效。

关 键 词:枸杞糖肽  非酒精性脂肪肝  临床疗效  不良反应
修稿时间:2008年1月16日

Clinical research of fructus lycii glucopeptide on patients with nonalcoholic fatty liver disease
Institution:XING Ming-you, LIU Lu, QIAN Dong-bin, et al. Infectious Department of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ( Wuhan Hubei, 430030) China
Abstract:Objective: To investigate the therapeutic effect and adverse reaction of fructus lycii glucopeptide on patients with nonalcoholic fatty liver disease. Methods: By random control study, 82 cases of NAFLD were divided into 2 groups (41 cases, respectively) . The patients in treatment group were administrated with caps of fructus lycii glucopeptide (30mg po bid), while the patients in control group were treated with tabs of glucurolactone (200mg po tid), both lasting 6 months. The clinical manifestations, liver function (ALT, AST, TBil, GGT), blood fat (TG, TCh, LDL-C, HDL-C), type-B ultrasonic findings and drug adverse reactions were observed and recorded before treatment and after 3-month or 6-month treatment. Results: The effective rate of 6-month treatment group (70. 7% ) was higher than that of control group (P 〈0. 05) , and also higher than 3-month treatment group ( P 〈 O. 05 ) . The level of ALT, AST, GGT were significantly decreased after treatment in both groups, with a favorable turn about all the items associated with blood fat. The above changes were especially apparent in treatment group compared with its per-treatment counterpart (P 〈 O. O1 or P 〈 O. 05 ), showing a better therapeutic effect than in con- trol group ( P 〈 O. O1 or P 〈 O. 05 ) . There was one case in the treatment group manifesting adverse reaction during the therapy. Conclusion: Fructus lycii glucopeptide has a marked therapeutic effect on the patients with NAFLD, and a good safety in clinic application. A longer course of treatment produces a better therapeutic effect.
Keywords:fructus lycii glucopeptide  nonalcoholic fatty liver disease (NAFLD)  therapeutic effect  adverse reaction
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号